KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Adult T-cell Leukemia-Lymphoma Clinical Trial

Official title:

Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01626664
• Other study ID #: PROTOCOL 0761-009
• Status: Completed
• Phase: Phase 2
• Start date: June 2012
• Est. completion date: February 2018

Study information

• Verified date: April 2024
• Source: Kyowa Kirin Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).

Description:

CCR4 expression in ATL patients has been demonstrated to be very high and has been associated with shorter survival compared with CCR4-negative patients. KW-0761, a monoclonal antibody targeted to CCR4, has been shown to be safe and tolerable in several clinical trials in subjects with a variety of T-cell malignancies, including ATL, mycosis fungoides and Sézary syndrome. The objective of this study is to estimate the overall response rate of KW-0761 for subjects with relapsed or refractory ATL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: February 2018
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and female subjects = 18 years of age

• Confirmed diagnosis of ATL (excluding smoldering subtype)

• Subjects must currently have evidence of disease in at least one of the following:

• Lymph nodes

• Extranodal masses

• Spleen or liver

• Skin

• Peripheral blood

• Bone marrow

• Relapsed or refractory after at least one prior systemic therapy regimen for ATL;

• Eastern Cooperative Oncology Group (ECOG) performance status score of = 2 at study entry

• Resolution of all clinically significant toxic effects of prior cancer therapy to grade =1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI-CTCAE, v.4.0)

• Adequate hematological, hepatic and renal function

Exclusion Criteria:

• Smoldering subtype of ATL;

• Lymphomatous or acute subtype subject with > 2 prior systemic therapy regimens and who has not achieved a response (CR or PR) or maintained stable disease for at least 12 weeks on last immediate prior therapy;

• History of allogeneic transplant;

• Autologous hematopoietic stem cell transplant within 90 days of study entry;

• Untreated human immunodeficiency virus (HIV)

• Has known hepatitis C. Patients who are hepatitis C antibody positive but are hepatitis C quantitative PCR negative may be enrolled;

• Has hepatitis B based on PCR testing for hepatitis B virus DNA. Patients who are hepatitis B core antibody positive but PCR negative may be enrolled if placed on appropriate anti-hepatitis B virus prophylaxis prior to commencing treatment with KW-0761. Patients who are hepatitis B core antibody positive based on prior vaccination need not receive prophylaxis;

• Have had a malignancy in the past two years except non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current PSA < 0.1 µg/mL, treated thyroid cancer or cervical carcinoma in situ or ductal/lobular carcinoma in situ of the breast who is currently without evidence of disease;

• Clinical evidence of central nervous system (CNS) involvement or metastasis. In subjects suspected of having CNS disease, an MRI of the brain and/or lumbar puncture should be done to confirm;

• Psychiatric illness, disability or social situation that would compromise the subject's safety or ability to provide consent, or limit compliance with study requirements;

• Significant uncontrolled intercurrent illness

• Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins;

• Known active autoimmune diseases will be excluded (For example; Grave's disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease);

• Is pregnant (confirmed by beta human chorionic gonadotrophin [ß-HCG]) or lactating.

• Prior treatment with KW-0761;

• Initiation of treatment with systemic corticosteroids while on study is only permitted for acute and brief complications of underlying disease (e.g., hypercalcemia) or for treatment related side effects (e.g., including pre-medication for infusion reaction, nausea and vomiting). Subjects on systemic corticosteroids prior to enrollment must be off for 7 days before initiation of study treatment, unless specifically indicated for the treatment of hypercalcemia. (subjects may receive inhalation corticosteroids and replacement doses of systemic corticosteroids as needed);

• Initiation of treatment with topical corticosteroids while on study is not permitted except to treat an acute rash. Subjects on a stable dose of medium or low potency topical corticosteroids for at least 4 weeks prior to Pre-treatment Visit may continue use at the same dose, although the investigator should attempt to taper the use to lowest dose tolerable;

• Have had interferon-a and/or zidovudine within 1 week, or anti-neoplastic chemotherapy, radiation, immunotherapy, or investigational medications within 2 weeks of first study treatment;

• Subjects on any immunomodulatory drug. Subjects on any immunomodulatory drug within 4 weeks of their first dose of KW-0761 are also excluded.

Related Conditions & MeSH terms

• Adult T-cell Leukemia-Lymphoma
• Leukemia
• Leukemia, T-Cell
• Leukemia-Lymphoma, Adult T-Cell
• Lymphoma

Intervention

Biological:
• KW-0761
1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression

Drug:
• Pralatrexate
30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
• gemcitabine plus oxaliplatin
gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
• DHAP
dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression

Locations

Country	Name	City	State
Belgium	Cliniques Universitaires Saint-Luc	Bruxelles
Brazil	Hospital Universitario Professor Edgard Santos- UFBA	Salvador, Bahia
Brazil	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo	Sao Paulo- SP
France	CHU de Fort de France	Fort De France Cedex
France	Hospital Necker	Paris
Peru	Hospital Nacional Edgardo Rebagliati Martins	Lima
Peru	Instituto Oncologico Miraflores	Lima
United Kingdom	Guy's Hospital	London
United Kingdom	Imperial College	London
United Kingdom	Sandwell General Hospital	West Midlands
United States	National Cancer Institute	Bethesda	Maryland
United States	Montefiore Medical Center	Bronx	New York
United States	Northwestern University	Chicago	Illinois
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	University of Miami / Sylvester Comprehensive Cancer Center	Miami	Florida
United States	Columbia Presbyterian	New York	New York
United States	Memorial Sloan Kettering	New York	New York
United States	Weill Cornell Medical College	New York	New York
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Kyowa Kirin, Inc.

Countries where clinical trial is conducted

United States,  Belgium,  Brazil,  France,  Peru,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate	Overall Response Rate was determined based on the response in all compartments (lymph nodes, extranodal masses, spleen/liver, skin, peripheral blood, and bone marrow), referencing Tsukasaki, 2009 as follows: Complete Response (CR) = All compartments involved with disease must be CR; Uncertified Complete Response (CRu) = > 75% decrease in lymph nodes and/or extranodal disease with all other compartments involved with disease CR; Partial Response (PR) = If any compartment is CR/PR and all other compartments involved with disease are at least SD; Stable Disease (SD) = All compartments involved with disease are SD; Progressive Disease (PD) = PD in any compartment.; Lymph node and extranodal masses response =50% decrease by CT, skin response =50% decrease in mSWAT score; blood response =50% decrease in malignant cells by flow cytometry; normal bone marrow if abnormal at baseline. PD equals New or =50% increase in any compartment.	every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first
Secondary	Progression Free Survival	Progression-free survival was defined as the time from the first date of treatment until the date that PD or death was first reported. Disease progression included PD in any compartment per ATL response criteria, clinical progression at the end of the randomized treatment, or disease progression reported during the follow-up period. The date of PD was the earliest date at which disease progression could be declared.	From date of randomization until the date of first documented progression, start of alternative therapy, or date of death from any cause, whichever came first, up to 36 months
Secondary	Overall Survival	The estimates and summary statistics for OS were calculated based on Kaplan-Meier method, and the median OS was 4.9 months for subjects randomized to the mogamulizumab group versus 6.87 months for subjects randomized to the Investigator's Choice group.	up to 36 months
Secondary	Change in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score	The FACT-Lym consists of a 27-item general core questionnaire (i.e., Functional Assessment of Cancer Therapy - General [FACT-G]) and a 15-item disease-specific questionnaire (Lymphoma Subscale). The FACT-G includes 4 domains: physical well-being, social/family well-being, emotional well-being, and functional well-being. The total FACT-Lym score (0-168) was obtained by summing individual subscale scores. Higher scores for the scales indicate better quality of life. Change was calculated as the value at the last observation minus the value at baseline.	From date of randomization until the date of first documented progression, up to 36 months